---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-255083"
form_type: "8-K"
ticker: "PMVP"
cik: "0001699382"
company_name: "PMV Pharmaceuticals, Inc."
filed_at: "2023-10-12T23:59:59+00:00"
generated_at: "2026-06-10T00:49:45.021685+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# PMV Pharma: PC14586 Phase 1 shows 38% ORR at RP2D; registrational Phase 2 planned early 2024

## Summary
- Confirmed ORR 38% (6/16) at RP2D 2000 mg daily in TP53 Y220C/KRAS wild-type patients; median DoR 7 months.
- Responses across ovarian, breast, prostate, lung, endometrial cancers; 34% ORR in efficacious dose range (13/38).
- Well tolerated: most TRAEs Grade 1-2 (nausea, vomiting, creatinine increase); only 3% discontinuation due to TRAE.
- RP2D selected after End of Phase 1 meeting with FDA in Q3 2023; Phase 2 registrational trial to start early 2024.
- Study enrolled heavily pretreated patients (median 3 prior lines); no approved therapies targeting p53 currently exist.

## SEC filing metadata
- accession: 0001193125-23-255083
- form_type: 8-K
- ticker: PMVP
- cik: 0001699382
- company_name: PMV Pharmaceuticals, Inc.
- filed_at: 2023-10-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1699382/000119312523255083/0001193125-23-255083-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1699382/000119312523255083/d534012d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-255083
- JSON: https://secwatch.observer/filing/0001193125-23-255083.json
- Plain text: https://secwatch.observer/filing/0001193125-23-255083.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.